TetraLogic Pharmaceuticals Announces Conference Call With Dr. Marc Pellegrini Of The Walter and Eliza Hall Institute of Medical Research To Discuss Tetralogic Infectious Disease Program

Published: Jun 13, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MALVERN, Pa., June 13, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) ("Company") today announced that it will host a conference call and live audio webcast on Monday, June 16, 2014 at 08:00 a.m. Eastern Time with Dr. Marc Pellegrini, Laboratory Head, Infection and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. Dr. Pellegrini will review preclinical studies indicating the potential for broad applicability of TetraLogic's lead compound, birinapant, in models of infectious disease, including Hepatitis B. The Company will also discuss future planned clinical activities, including a Phase 1 clinical trial of birinapant in patients with chronic Hepatitis B infection, which the Company intends to commence in late 2014 and for which Dr. Pellegrini will play a key leadership role.

Help employers find you! Check out all the jobs and post your resume.

Back to news